The effect of disopyramide phosphate (DP) infusion (1mg/Kg and 2mg/Kg BW) on ventricular fibrillation threshold (VFT) was studied in anesthetized dogs. In the 1mg/Kg group, the VFT increased 47% above the control level immediately after infusion. In the 2mg/Kg group, a delayed increase in VFT was observed after the initial period and VFT was not correlated with the plasma concentration of DP. This phenomenon was abolished by pretreatment with methacholine. These results suggested an anticholinergic action of DP on the VFT. In the ischemic dogs produced by acute coronary occlusion, DP prevented a decrease in VFT. ENTRICULAR fibrillation is one of the major causes of death in patients with acute myocardial infarctions. Ventricular tachyarrhythmias or premature ventricular contractions falling within the vulnerable period of the previous beat may initiate ventricular fibrillation. The determination of the ventricular fibrillation threshold (VFT) has been used experimentally to assess quantitatively the influence of drugs upon the resistance of the heart to fibrillation. Several investigations1),2) have demonstrated that procainamide and quinidine are effective in suppressing both ventricular arrhythmias and raised VFT. However, there are no data regarding the effects of disopyramide phosphate (DP), a type 1 antiarrhythmic agent, despite its effectiveness in suppressing ventricular arrhythmias.
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3) The purpose of the present investigation is to determine whether DP can alter electrical stability of normal and ischemic myocardium, as measured by the VFT. Furthermore, in parallel experiments, we studied whether the anticholinergic property of DP 
RESULTS
Plasma concentration of DP: Fig. 1 shows plasma concentrations of DP after a single dose of 1mg/Kg and 2mg/Kg body weight. As shown in this figure, plasma levels of DP declined rapidly from a maximum value immediately after the infusion. The slope of the decrease was most steep In the latter group, the maximum rise in VFT was attained in 15min following a small initial VFT increase. mean VFT (Fig. 6 ) was 14.5 mA. During ischemia prior to 2mg/Kg DP administration, the VFT decreased from 14.5 to 9 mA, a 38% decrease from the control value. After DP infusion, the mean VFT during acute coronary occlusion increased to a maximum of 17 mA after 15min of infusion. This maximum value exceeded the control value (p<0.05). These values of VFT after DP contrasted with the results of control studies (Fig. 5) , indicating that DP prevented a reduction in VFT during acute ventricular ischemia. 
DISCUSSION
The VFT has been used as an index of vulnerability to fibrillation and may be a useful general indicator for drugs with potential antiarrhythmic properties.4) DP is a new antiarrhythmic drug with a pharmacological profile of action similar to quinidine.5) DP has been said to possess an important anticholinergic property in addition to its myocardial depressant action.6),7) Thus clinically observed effects of DP and quinidine may be the net results of both " excitatory " (anticholinergic) and depressant properties.8)
Although several investigators1),2) reported studies of the effects of type 1 antiarrhythmic agents on the VFT, there are no data about the effects of DP on the VFT. Yoon et al1) studied the effects of procainamide on the VFT of normal and ischemic ventricles with simultaneous procainamide blood levels. Procainamide at therapeutic blood levels increased the mean fibrillation threshold from the control value of 16 to 30 mA (88% increase) in the normal ventricles. The effect was less pronounced during acute coronary occlusion and the mean fibrillation threshold increased from 8 to 13 mA (63% increase) at therapeutic procainamide blood levels. The increase, peak level and decrease in blood concentration paralleled changes in fibrillation threshold.
In our DP study, this drug in a dose of 1mg/Kg increased the mean fibrillation threshold from a control value of 12 to 17.6 mA (47% increase) in the normal ventricles. As in procainamide studies, the increase, peak level and decrease in blood concentration paralleled changes in fibrillation threshold. However, in a 2mg/Kg infused group, the VFT curve after infusion was different from the 1mg/Kg group. The peak level of VFT was delayed and the mean VFT was not dependent on the plasma concentration of DP. We thought that some net effects of DP might influence the results of these VFT values in the 2mg/Kg administered group. As stated above, DP has been said to possess significant anticholinergic properties in addition to their myocardial depressant action.6),7) Yeh et al7) found that DP had much more potent vagolytic effect than quinidine. Atropine as a representative of anticholinergic drugs has been said to decrease VFT in normal ventricles.9) Thus it is possible that the anticholinergic property of DP over a certain degree of plasma concentration in the immediate phase after 2mg/Kg infusion antagonized the increase of VFT, which reflects the antifibrillatory action of DP (dose related response). Also, the delayed rise in the 2mg/Kg group occurs when the plasma DP concentration declines to a level within the range that induces the immediate rise in the 1mg/Kg group. This implies that the anticholinergic properties of DP are most prominent at 
